The Effect of Prognostıc Factors and Potentıal Treatment Regımens on Fatality Covid-19 Patıents
The ongoing outbreak of the coronavirus disease 2019 (COVID-19), as named by the World Health Organization, has millions of confirmed cases worldwide and has claimed hundreds of thousands of lives. The virus was named SARS-CoV-2 in February by the International Committee on Taxonomy of Viruses. COVID-19 presents as fever, dry cough, dyspnea, headache, and pneumonia. In a small subset of severe cases, the disease quickly progresses to respiratory failure and even death. This study aimed to know the effects of clinical and laboratory features on investigated death. The diagnosis was based on typical findings in thoracic computed tomography (CT) and positive results of the Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) SARS-CoV-2. The demographic characteristics of COVID-19 patients treated, accompanying comorbid conditions and laboratory criteria (blood lymphocyte counts, C Reactive Protein (CRP), D-dimer, Interleukin 6 (IL-6), blood neutrophil count/lymphocyte counts) were collected retrospectively. The results show that 121 cases, 66 (54.54%) were male, 55 (45.46%) were female, and the mean age was ± Std (Min-Max), 59.63 ± 17.4 (22-91). Neutrophil percentage (p = 0.027), neutrophil / lymphocyte ratio (NE / LE) (p = 0.028), CRP (p = <0.001), PCT (p = 0.004), D dimer (p = 0.021) and IL 6 (p = 0.047) in patients with a fatal course, higher values were found than those recovered. Blood lymphocyte count (p = 0.001) and percent (p <0.001) were lower. Number of blood white spheres (p = 0.010), blood neutrophil counts (p = 0.001) and percentage (p <0.001), NE / LE (p0.001), CRP (p <0.001), PCT (p = 0.003) and IL -6 (p <0.001) levels were higher in patients with severe clinical findings than in mild cases. The case death rate was observed as 9%. Covid-19 patients should consider blood neutrophil percentage, blood lymphocyte count, blood lymphocyte percentage, NE / LE, CRP, D dimer, and IL 6 values as an early warning in terms of prognosis. More experience was needed to assess the benefits of immune plasma, tocilizumab, IVIG treatments, and remdesivir therapy recently introduced to the treatment protocol.
Ai, T., Yang, Z., Hou, H., Zhan, C., Chen, C., Lv, W., Tao Q, Sun Z, & Xia, L. (2020). Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology, 296(2), E-32-E40. DOI: 10.1148/radiol.2020200642
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020). Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. Jama, 323(16), 1612-1614. DOI: 10.1001/jama.2020.4326
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19). In Statpearls [internet]. Stat Pearls Publishing.
Chan, K. S., Lai, S. T., Chu, C. M., Tsui, E., Tam, C. Y., Wong, M. M. L., ... & Wong, V. C. W. (2003). Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Medical Journal, 9: 399-406.
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K., ... & Mulders, D. G. (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 25(3), 270-280. DOI:10.2807/1560-7917.ES.2020.25.3.2000045
Fang, Y., Zhang, H., Xie, J., Lin, M., Ying, L., Pang, P., & Ji, W. (2020). Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology, 296(2),E-115-E117. DOI: 10.1148/radiol.2020200432
Gao, Y., Li, T., Han, M., Li, X., Wu, D., Xu, Y., ... & Wang, L. (2020). Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. Journal of medical virology.92, 791-796. DOI:10.1002/jmv.25770
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506. DOI: 10.1016/S0140-6736(20)30183-5
Ji, Y., Ma, Z., Peppelenbosch, M. P., & Pan, Q. (2020). Potential association between COVID-19 mortality and health-care resource availability. The Lancet. Global health, 8(4), e480. DOI: 10.1016/S2214-109X (20)30068-1
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., ... & Xing, X. (2020). Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine, 382:1199–1207. DOI: 10.1056/NEJMoa2001316
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., ... & Bi, Y. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 395(10224), 565-574. DOI: 10.1016/S0140-6736(20)30251-8
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., ... & Miao, X. (2020). Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA neurology, 77(6), 683-690. DOI: 10.1101/2020.02.22.20026500.
Mardani, R., Vasmehjani, A. A., Zali, F., Gholami, A., Nasab, S. D. M., Kaghazian, H., ... & Ahmadi, N. (2020). Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study. Archives of Academic Emergency Medicine, 8(1), E-43.
Moutchia, J., Pokharel, P., Kerri, A., McGaw, K., Uchai, S., Nji, M., & Goodman, M. (2020). Clinical Laboratory Parameters Associated with Severe or Critical Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis. medRxiv. DOI: 10.1101/2020.04.24.20078782
Nebraska Medicine (2020). COVID-19 Antiviral and pharmacotherapy recommendations. Nebraska Medicine
The Republic of Turkey Ministry of Health. (2020). COVID-19 Weekly Situation Report, 29/06/2020–05/07/2020, Turkey. The Republic of Turkey Ministry of Health
The Republic of Ministry of Health, General Directorate of Public Health. (2020). Covid-19 (SARS-CoV-2 Infection), Adult Patient Treatment, Scientific Advisory Board Study, August 2, 2020. The Republic of Ministry of Health, General Directorate of Public Health
Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., ... & Huang, X. (2020). Clinical features and treatment of COVID‐19 patients in northeast Chongqing. Journal of medical virology. DOI: 10.1002/jmv.25783.
Wang D, Hu B, Hu C, Zhu, F., Liu, X., Zhang J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020, 323 (11):1061–1069. DOI: 10.1001/jama.2020.1585
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020). Detection of SARS-CoV-2 in different types of clinical specimens. Jama, 323(18), 1843-1844. DOI: 10.1001/jama.2020.3786
Wax, R. S., & Christian, M. D. (2020). Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anesth/J Can Anesth 67, 568–576 . DOI: 10.1007/s12630-020-01591-x
WHO. (2020). Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). World Health Organization.
WHO. (2020). Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization.WHO. (2020). WHO statement regarding a cluster of pneumonia cases in Wuhan, China?. World Health Organization.
Yang, A. P., Liu, J., Tao, W., & Li, H. M. (2020). The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. International immunopharmacology, 84, 106504. DOI: 10.1016/j.intimp.2020.106504
Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., ... & Wang, Y. (2020). Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine. DOI: 10.1016/S2213-2600(20)30079-5
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Guan, L. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 395 (10229): 1054-1062. DOI: 10.1016/S0140-6736(20)30566-3
Copyright (c) 2020 JURNAL INFO KESEHATAN
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Ownership of copyright
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by JURNAL INFO KESEHATAN and its licensors.
JURNAL INFO KESEHATAN grants to you a worldwide non-exclusive royalty-free revocable license to:
- view this website and the material on this website on a computer or mobile device via a web browser;
- copy and store this website and the material on this website in your web browser cache memory; and
- print pages from this website for your use.
- All articles published by JURNAL INFO KESEHATAN are licensed under the Creative Commons Attribution 4.0 International License. This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited.
JURNAL INFO KESEHATAN does not grant you any other rights in relation to this website or the material on this website. In other words, all other rights are reserved.
For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or JURNAL INFO KESEHATAN prior written permission.
You may request permission to use the copyright materials on this website by writing to firstname.lastname@example.org.
Enforcement of copyright
JURNAL INFO KESEHATAN takes the protection of its copyright very seriously.
If JURNAL INFO KESEHATAN discovers that you have used its copyright materials in contravention of the license above, JURNAL INFO KESEHATAN may bring legal proceedings against you seeking monetary damages and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of JURNAL INFO KESEHATAN copyright materials that contravenes or may contravene the license above, please report this by email to email@example.com
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to firstname.lastname@example.org.